COGT Company Profile and Key Details

COGT has shown sold momentum, gaining 14.79% over the past week and 143.44% over the past quarter, though year-to-date performance is up 12.33%. Short-term trend indicators are mixed aligned (SMA20 4.96%, SMA50 4.64%, SMA200 88.54%). The stock’s 14-day RSI is 57.71 (neutral), while the ATR of 1.93 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -9.76% below its high and over 960.75% above its low. Average 10-day trading volume of 1.73 million shares is below the 3-month average of 2.15 million, indicating normal recent market interest.

Cogent Biosciences, Inc. has 139.70 million shares outstanding. The public float is 102.75 million shares, elevated short interest at 10.62% of float. This equals 13.07 million shares. The short ratio is 10.0 days. Institutional investors hold 105.53% of the float. Insiders own 0.04%. FROST PHILLIP MD ET AL holds 15.73 million shares, Schulke Ryan has 6.36 million shares and Fairmount Funds Management LLC has 5.50 million shares. Over the past six months, insider transactions show net selling. They sold 3.81 million shares across 5 transactions.

Cogent Biosciences, Inc. generated EPS of -$2.56 over the past year. Five-year average earnings growth is 30.89%. The latest quarter delivered EPS of -$0.71. The next quarter is forecast at -$0.53. Next year's EPS is expected at $9.10. Analyst sentiment is bullish. Analyst rating data shows there are 10 Strong Buy ratings, 10 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $67.00 to $9.00. The high target offers 79.91% upside. The low target suggests -75.83% downside. The mean target is $31.13. This offers -16.41% upside. Cogent Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended November 07, 2025, missed forecasts by 30.93%. The prior quarter beat by -3.64%. Over the last six quarters, Apple has recorded several small beats. These include 7.27% in August 06, 2024.

Cogent Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.87. This means the shares are trading above this model’s fair value.

Cogent Biosciences, Inc. (NASDAQ:COGT) closed at $37.24 USD, losing -$1.65 (-4.24%) from the previous close of $38.89. The stock is currently mid-range between its 52-week high and low $3.72 and $43.73. With a market capitalization of about $6.04 billion, Cogent Biosciences, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.47). Key stats such as the average daily volume over the past year has been around 2.19 million shares, volume is running light vs its 52-week average. Headquartered in Waltham, MA, Cogent Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Andrew R. Robbins, the company employs approximately 205 people and listed since March 29, 2018. Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases.

Cogent Biosciences, Inc. trades at a P/E ratio of -7.77, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.02 trading at moderately above to book value. The P/FCF stands at -23.08, also below market averages.

Cogent Biosciences, Inc. (NASDAQ:COGT) shares are up 12.33% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cogent Biosciences, Inc. trading at a premium to the broader market with a P/E of -7.77. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $23.38, suggesting -37.22% downside. Our AI forecast model points to short-term strength (4.75% over two weeks), a medium-term fall (-18.98% over three months), and a longer-term gain (22.56% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Cogent Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.75%, with price expected at $39.01 by March 17, 2026, within a range of $37.57 to $40.57 3-Month Outlook: Projected fall of -18.98%, reaching $30.17 by June 01, 2026, with a range of $29.79 to $30.64. 1-Year Outlook: Projected gain of 22.56%, with price at $45.64 by March 03, 2027, within a range of $42.69 to $47.97.